Global Scientific Director
Novo Nordisk
Zurich, Zurich, Switzerland
Dr Thomas Porstmann is the medical affairs lead for concizumab working as Global Scientific Director in the rare blood disorders medical affairs team at Novo Nordisk Zurich, Switzerland.
Dr Porstmann studied biochemistry & molecular biology at the Friedrich Schiller University Jena in Germany. He obtained a PhD in applied cancer research from the University College London/Cancer Research UK London Research Institute, followed by post-doctoral research at ETH Zurich in obesity and diabetes research. He has also obtained a Diploma of Advanced Studies in Pharmaceutical Medicine (European Center of Pharmaceutical Medicine) from the University of Basel.
Dr Porstmann has over 12 years of medical affairs experience working for GSK and Pfizer, before joining Novo Nordisk in March 2018.
Sunday, June 23, 2024
13:45 – 14:45 ICT